Literature DB >> 3137169

Parameters of Mycoplasma pneumoniae infection in Syrian hamsters.

M F Barile1, D K Chandler, H Yoshida, M W Grabowski, R Harasawa, S Razin.   

Abstract

An animal model for evaluating the potency of Mycoplasma pneumoniae vaccines was developed with hamsters. Factors that influence hamster infection by M. pneumoniae were defined, and parameters for assessment of intensity of pulmonary disease were established. Colonization of hamster lungs was determined by culture, and intensity of lung disease was assessed histopathologically and expressed numerically as a lung pathological score. Intratracheal inoculation of the challenge was superior to the intranasal or aerosol route for inducing a consistent degree of lung disease. A challenge dose of 10(6) CFU inoculated intratracheally produced lung colonization and significant reproducible lung pathological scores in essentially all unvaccinated animals. The peak of infection, as determined by these criteria, was at about 2 weeks after challenge. Animals over 6 weeks of age were preferable for the test, since younger animals exhibited a lower lung pathological score even though they showed the same degree of lung colonization. The hamster assay developed provides a dependable experimental system for testing the protective potency of M. pneumoniae vaccines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137169      PMCID: PMC259586          DOI: 10.1128/iai.56.9.2443-2449.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Protective Effect of Vaccines in Experimental Mycoplasma pneumoniae Disease.

Authors:  G W Fernald; W A Clyde
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

2.  Immunoglobulin-containing cells in lungs of hamsters infected with Mycoplasma pneumoniae.

Authors:  G W Fernald; W A Clyde; J Bienenstock
Journal:  J Immunol       Date:  1972-05       Impact factor: 5.422

3.  Characteristics of virulent, attenuated, and avirulent Mycoplasma pneumoniae strains.

Authors:  R P Lipman; W A Clyde; F W Denny
Journal:  J Bacteriol       Date:  1969-11       Impact factor: 3.490

4.  Ciliostatic, hemagglutinating, and proteolytic activities in a cell extract of Mycoplasma pneumoniae.

Authors:  D K Chandler; M F Barile
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

5.  Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.

Authors:  M F Barile; D K Chandler; H Yoshida; M W Grabowski; R Harasawa; O A Ahmed
Journal:  Isr J Med Sci       Date:  1981-07

6.  The principal protein antigens of isolates of Mycoplasma pneumoniae as measured by levels of immunoglobulin G in human serum are stable in strains collected over a 10-year period.

Authors:  A C Vu; H M Foy; F D Cartwright; G E Kenny
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

7.  Unexpectedly high frequency of antibody to Mycoplasma pneumoniae in human sera as measured by sensitive techniques.

Authors:  H Brunner; B Prescott; H Greenberg; W D James; R L Horswood; R M Chanock
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

8.  Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.

Authors:  M F Barile; D K Chandler; H Yoshida; M W Grabowski; S Razin
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

9.  Protective efficacy of Mycoplasma pneumoniae polysaccharides.

Authors:  H Brunner
Journal:  Isr J Med Sci       Date:  1981-07

10.  Immunopathology of experimental Mycoplasma pneumoniae disease.

Authors:  W A Clyde
Journal:  Infect Immun       Date:  1971-12       Impact factor: 3.441

View more
  20 in total

1.  In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.

Authors:  M Takahata; M Shimakura; R Hori; K Kizawa; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Analysis of three different repeated DNA elements present in the P1 operon of Mycoplasma pneumoniae: size, number and distribution on the genome.

Authors:  K Ruland; R Wenzel; R Herrmann
Journal:  Nucleic Acids Res       Date:  1990-11-11       Impact factor: 16.971

3.  A spontaneous hemadsorption-negative mutant of Mycoplasma pneumoniae exhibits a truncated adhesin-related 30-kilodalton protein and lacks the cytadherence-accessory protein HMW1.

Authors:  G Layh-Schmitt; H Hilbert; E Pirkl
Journal:  J Bacteriol       Date:  1995-02       Impact factor: 3.490

4.  Sequence divergence in the ORF6 gene of Mycoplasma pneumonia.

Authors:  K Ruland; R Himmelreich; R Herrmann
Journal:  J Bacteriol       Date:  1994-09       Impact factor: 3.490

Review 5.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

Authors:  K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; N Suyama; K Tomono
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.

Authors:  M Kaku; K Ishida; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; K Tomono; N Suyama
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.

Authors:  Y Gohara; S Arai; A Akashi; K Kuwano; C C Tseng; S Matsubara; M Matumoto; T Furudera
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.

Authors:  M F Barile; D K Chandler; H Yoshida; M W Grabowski; S Razin
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

10.  The immunodominant 90-kilodalton protein is localized on the terminal tip structure of Mycoplasma pneumoniae.

Authors:  G Franzoso; P C Hu; G A Meloni; M F Barile
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.